An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy

被引:1
|
作者
Jiang, Wei [1 ,3 ]
Tie, Zuoxiu [3 ]
Yu, Chi [2 ]
Chen, Yu [4 ]
Liu, Dan [2 ]
Li, Bin [1 ]
机构
[1] Guangxi Univ Sci & Technol, Med Coll, Dept Biochem & Mol Biol, Liuzhou 545005, Peoples R China
[2] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Shenyang 110142, Peoples R China
[3] Nanjing Univ, Coll Engn & Appl Sci, MOE Key Lab High Performance Polymer Mat & Technol, Nanjing 210033, Peoples R China
[4] Commonwealth Sci & Ind Res Org CSIRO Mfg, Clayton, Vic 3168, Australia
关键词
Energy metabolism; Cell dormancy; Lysosome; Glutathione; Cisplatin prodrug; DRUG; POLYMER;
D O I
10.1016/j.biomaterials.2023.122354
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Although inhibiting the energy metabolism of tumor cells has become an effective measure to enhance chemotherapy, tumor cells can still escape the lethal effect of chemotherapy by entering a dormancy state with low-energy expenditure. Herein, the glutathione (GSH)-responsive nanoplatform (C-A-D NPs) were constructed to inhibit energy metabolism and lysosomal activity of tumor cells, thereby forcing tumor cells to remain vulnerable to cisplatin. In this system, cisplatin prodrug was reduced to cisplatin by GSH, and D-peptide and apoptozole (Az) were released to inhibit the energy metabolism and autophagy-lysosome pathway of tumor cells. The suppressed autophagy-lysosome pathway prevents tumor cells from entering a low-energy dormancy state, resulting in the loss of resistance to the lethal effect of cisplatin with high-energy expenditure and insufficient energy supply. Such engineered nanoplatform effectively enhances the chemotherapeutic effect of cisplatin by inhibiting intracellular energy metabolism and lysosomal activity, showing great clinical prospects.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effect of long-term peripheral neuropathy induced on cisplatin-based chemotherapy or radiation to the retroperitoneum in testicular germ cell tumor survivors.
    Chovanec, Michal
    Galikova, Dominika
    Vasilkova, Lucia
    De Angelis, Valentina
    Rejlekova, Katarina
    Obertova, Jana
    Sycova-Mila, Zuzana
    Palacka, Patrik
    Kalavska, Katarina
    Svetlovska, Daniela
    Mladosievicova, Beata
    Mardiak, Jozef
    Mego, Michal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
    I. N. Olver
    P. Grimison
    M. Chatfield
    M. R. Stockler
    G. C. Toner
    V. Gebski
    R. Harrup
    C. Underhill
    G. Kichenadasse
    N. Singhal
    I. D. Davis
    A. Boland
    A. McDonald
    D. Thomson
    Supportive Care in Cancer, 2013, 21 : 1561 - 1568
  • [33] Predicting factors for collection of peripheral blood stem cells in patients with advanced germ cell tumors after cisplatin-based combination chemotherapy
    Muramaki, M
    Miyake, H
    Hara, S
    Kamidono, S
    Hara, I
    ONCOLOGY REPORTS, 2003, 10 (05) : 1545 - 1549
  • [34] Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity
    Yang, Ruyue
    Yue, Wenhui
    Hu, Dong
    Wang, Guidan
    Mao, Longfei
    Huang, Jiahe
    Wang, Huili
    Liang, Gaofeng
    CHEMISTRYOPEN, 2024, 13 (07)
  • [35] CLINICAL PATTERNS AND TREATMENT OUTCOMES IN GERMINOMA PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY AND LOCAL IRRADIATION: THE EXPERIENCE FROM JAPANESE PEDIATRIC BRAIN TUMOR CONSORTIUM
    Nakano, Yoshiko
    Okada, Keiko
    Kosaka, Yoshiyuki
    Nagashima, Tatsuya
    Hashii, Yoshiko
    Kagawa, Naoki
    Soejima, Toshihiro
    Osugi, Yuko
    Sakamoto, Hiroyuki
    Hara, Junichi
    NEURO-ONCOLOGY, 2014, 16 : 34 - 34
  • [36] Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?
    Koc, Gokhan
    Divrik, Taner Rauf
    Unlu, Nuri
    Bulut, Volkan
    Zorlu, Ferruh
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2011, 43 (04) : 1095 - 1100
  • [37] Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?
    Gokhan Koc
    Taner Rauf Divrik
    Nuri Unlu
    Volkan Bulut
    Ferruh Zorlu
    International Urology and Nephrology, 2011, 43 : 1095 - 1100
  • [38] Polyphotosensitizer-Based Nanoparticles with Michael Addition Acceptors Inhibiting GST Activity and Cisplatin Deactivation for Enhanced Chemotherapy and Photodynamic Immunotherapy
    Zhao, Qinxin
    Liang, Ganghao
    Guo, Boda
    Wang, Wenkuan
    Yang, Chao
    Chen, Dong
    Yang, Feiya
    Xiao, Haihua
    Xing, Nianzeng
    ADVANCED SCIENCE, 2023, 10 (13)
  • [39] Circulating tumor cells exhibit a tumor stemness defense phenotype in Head and Neck cancer subjects undergoing cisplatin based chemotherapy
    Pathak, Lekhika
    Pal, Bidisha
    Talukdar, Joyeeta
    Saikia, Partha Jyoti
    Sandhya, Sorra
    Tasabehji, Wale
    Li, Hong
    Phukan, Jyotirmoi
    Bhuyan, Anjan
    Patra, Sanjukta
    Das, Bikul
    CANCER RESEARCH, 2023, 84 (06)
  • [40] Telomerase activity and telomere length in testicular cancer tissues and residual tumor mass after cisplatin based chemotherapy
    Burger, AM
    Fiebig, HH
    Harnden, P
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 158 - 158